文献速递静脉血栓栓塞

住院静脉血栓栓塞症患者初始使用低分子肝素对直接口服抗凝药治疗临床影响:倾向评分匹配研究

Clinical Impact of Initial Low Molecular Weight Heparin Use in Hospitalised Patients with Venous Thromboembolism Treated with Direct Oral Anticoagulants: A Propensity Score Matched Study.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2026-06-12

本研究基于台湾2012至2022年全国住院数据库,纳入住院VTE并新处方DOAC的成人患者,按LMWH起始状态进行倾向评分匹配。在达比加群或艾多沙班组,LMWH起始与复发VTE、大出血或全因死亡无显著关联;在阿哌沙班或利伐沙班组,LMWH起始与更高复发VTE风险相关,但未增加大出血。两组药物间效应无显著差异。

要点

  • 阿哌沙班或利伐沙班组中,LMWH起始与更高复发VTE风险相关(SHR 1.81)。
  • LMWH起始未显著增加大出血或全因死亡风险,两组药物间效应无显著差异。

核心结论

  • 在达比加群或艾多沙班使用者中,LMWH起始与短期血栓或出血结局无显著差异。
  • 在阿哌沙班或利伐沙班使用者中,LMWH起始与更高复发VTE风险相关,但未增加大出血。
  • 两种药物组间LMWH效应无显著差异,需前瞻性研究和外部验证。

研究设计与样本

  • 回顾性队列研究,使用台湾2012至2022年全国住院数据库。
  • 纳入住院VTE并新处方DOAC的成人患者,按LMWH起始状态进行倾向评分匹配。

主要发现

  • 达比加群或艾多沙班组:LMWH起始与复发VTE无显著关联(2.2% vs. 1.5%;SHR 1.41,95%CI 0.90-2.21)。
  • 达比加群或艾多沙班组:LMWH起始与大出血无显著关联(0.9% vs. 0.7%;SHR 1.33,95%CI 0.69-2.54)。
  • 达比加群或艾多沙班组:LMWH起始与全因死亡无显著关联(5.3% vs. 4.5%;HR 1.16,95%CI 0.89-1.53)。
  • 阿哌沙班或利伐沙班组:LMWH起始与更高复发VTE风险相关(2.6% vs. 1.4%;SHR 1.81,95%CI 1.48-2.23)。
  • 阿哌沙班或利伐沙班组:LMWH起始与大出血无显著关联(0.7% vs. 0.6%;SHR 1.18,95%CI 0.83-1.69),与全因死亡无显著关联(4.4% vs. 4.2%;HR 1.04,95%CI 0.91-1.19)。

临床怎么用

  • 住院VTE患者使用达比加群或艾多沙班时,LMWH起始未显示短期临床结局获益或损害。
  • 使用阿哌沙班或利伐沙班时,LMWH起始与更高复发VTE风险相关,需权衡个体化抗凝策略。
  • 临床决策应结合DOAC种类和患者血栓风险,不应一概而论LMWH起始。

局限性

  • 回顾性观察性研究,存在残余混杂可能。
  • 结论需前瞻性研究和外部验证确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Treatment of venous thromboembolism (VTE) with direct oral anticoagulants (DOACs) follows established, agent specific, low molecular weight heparin (LMWH) initiation protocols. However, adherence to these protocols may be suboptimal in real world practice. This study evaluated the association between protocol adherence and thirty day clinical outcomes in hospitalised patients with VTE receiving DOAC therapy. METHODS: A retrospective cohort study using Taiwan's national hospitalisation database from 2012 to 2022 was conducted. Adults hospitalised for VTE and newly prescribed DOAC were included. Propensity score matching was performed by DOAC type based on LMWH initiation status. RESULTS: Among 29 182 patients, 6 683 received dabigatran or edoxaban and 22 499 received apixaban or rivaroxaban. After matching, 2 135 pairs in the dabigatran or edoxaban cohort and 9 858 pairs in the apixaban or rivaroxaban cohort were analysed. In the dabigatran or edoxaban group, LMWH lead in was not associated with recurrent VTE (2.2% vs. 1.5%; subdistribution hazard ratio [SHR] 1.41, 95% confidence interval [CI] 0.90 - 2.21), major bleeding (0.9% vs. 0.7%; SHR 1.33, 95% CI 0.69 - 2.54), or all cause mortality (5.3% vs. 4.5%; hazard ratio [HR] 1.16, 95% CI 0.89 - 1.53). In the apixaban or rivaroxaban group, LMWH lead in was associated with a higher risk of recurrent VTE (2.6% vs. 1.4%; SHR 1.81, 95% CI 1.48 - 2.23), but not with major bleeding (0.7% vs. 0.6%; SHR 1.18, 95% CI 0.83 - 1.69) or all cause mortality (4.4% vs. 4.2%; HR 1.04, 95% CI 0.91 - 1.19). The effect of LMWH vs. non-LMWH did not differ significantly between the two pharmacological groups. CONCLUSION: In this nationwide observational cohort, initiation with LMWH was not associated with differences in short term thrombotic or bleeding outcomes among dabigatran or edoxaban users. In contrast, among apixaban or rivaroxaban users, LMWH initiation was associated with a higher risk of recurrent VTE without increasing major bleeding. However, the estimates were not significantly different between the two pharmacological groups. Prospective studies and external validation are needed.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Hsu JC, Huang CY, Shu-Han Lin D, et al. Clinical Impact of Initial Low Molecular Weight Heparin Use in Hospitalised Patients with Venous Thromboembolism Treated with Direct Oral Anticoagulants: A Propensity Score Matched Study. Eur J Vasc Endovasc Surg. 2026. PMID: 42285279. doi:10.1016/j.ejvs.2026.06.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。